Showing results (1-10 of 102) with videos related to
Sort By:
Pageof 11
European Urology|May 20, 2023
Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap SyndromeChristopher J Logothetis, Andrew W HahnTherapeutic Advances in Medical Oncology|June 9, 2022
Missing the trees for the forest: most subgroup analyses using forest plots at the ASCO annual meeting are inconclusiveAndrew W Hahn, Nazli Dizman, Pavlos MsaouelEuropean Urology Focus|March 16, 2019
The Role of PD-L1 Testing in Advanced Genitourinary MalignanciesAndrew W Hahn, Deepika Sirohi, Neeraj AgarwalThe Medical Clinics of North America|May 29, 2016
New Approaches to Antibiotic Use and Review of Recently Approved Antimicrobial AgentsAndrew W Hahn, Rupali Jain, David H SpachClinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2021
An Evolving Role for AXL in Metastatic Renal Cell CarcinomaAndrew W Hahn, Daniel J George, Neeraj AgarwalHuman Vaccines & Immunotherapeutics|August 6, 2016
Immunotherapy of advanced renal cell carcinoma: Current and future therapiesDavid Gill, Andrew W Hahn, Guru Sonpavde, et al.Current Opinion in Urology|August 18, 2017
Novel androgen axis systemic therapies for metastatic hormone-sensitive prostate cancerAndrew W Hahn, Peter Hale, Nityam Rathi, et al.Cells|November 10, 2023
The Influence of Obesity on Outcomes with Immune Checkpoint Blockade: Clinical Evidence and Potential Biological MechanismsAndrew W Hahn, Neha Venkatesh, Pavlos Msaouel, et al.Immunotherapy|June 28, 2017
The future of immune checkpoint cancer therapy after PD-1 and CTLA-4Andrew W Hahn, David M Gill, Sumanta K Pal, et al.Current Treatment Options in Oncology|January 26, 2018
Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell CarcinomaDavid M Gill, Andrew W Hahn, Peter Hale, et al.Pageof 11